West Pharmaceutical Services, Inc. (WST) Expected to Announce Quarterly Sales of $415.53 Million
Analysts forecast that West Pharmaceutical Services, Inc. (NYSE:WST) will report sales of $415.53 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for West Pharmaceutical Services’ earnings. The lowest sales estimate is $411.50 million and the highest is $418.00 million. West Pharmaceutical Services reported sales of $382.30 million in the same quarter last year, which indicates a positive year over year growth rate of 8.7%. The company is expected to issue its next quarterly earnings report on Thursday, February 15th.
According to Zacks, analysts expect that West Pharmaceutical Services will report full-year sales of $415.53 million for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will post sales of $1.73 billion per share, with estimates ranging from $1.71 billion to $1.74 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.14. West Pharmaceutical Services had a return on equity of 14.47% and a net margin of 12.12%. The business had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. During the same period in the prior year, the business earned $0.53 EPS. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year.
Several research analysts have recently commented on WST shares. Stephens started coverage on West Pharmaceutical Services in a research report on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price target for the company. BidaskClub lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research report on Wednesday, September 27th. Wells Fargo & Company boosted their price target on West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Finally, Bank of America Corporation lowered West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price target for the company. in a research report on Tuesday, October 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $106.00.
Shares of West Pharmaceutical Services (NYSE WST) traded down $0.02 during mid-day trading on Tuesday, hitting $101.63. The company’s stock had a trading volume of 269,400 shares, compared to its average volume of 366,841. West Pharmaceutical Services has a twelve month low of $76.87 and a twelve month high of $103.36. The stock has a market cap of $7,547.81, a PE ratio of 43.81, a price-to-earnings-growth ratio of 2.17 and a beta of 1.14. The company has a quick ratio of 1.87, a current ratio of 2.59 and a debt-to-equity ratio of 0.15.
A number of institutional investors have recently bought and sold shares of the business. Oppenheimer Asset Management Inc. grew its stake in West Pharmaceutical Services by 3.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 35,936 shares of the medical instruments supplier’s stock valued at $3,460,000 after purchasing an additional 1,156 shares during the last quarter. Private Advisor Group LLC purchased a new stake in West Pharmaceutical Services during the 3rd quarter valued at about $202,000. BB&T Investment Services Inc. purchased a new stake in West Pharmaceutical Services during the 3rd quarter valued at about $417,000. Pier Capital LLC grew its stake in West Pharmaceutical Services by 1.5% during the 3rd quarter. Pier Capital LLC now owns 61,782 shares of the medical instruments supplier’s stock valued at $5,947,000 after purchasing an additional 917 shares during the last quarter. Finally, Stifel Financial Corp grew its stake in West Pharmaceutical Services by 10.1% during the 3rd quarter. Stifel Financial Corp now owns 22,270 shares of the medical instruments supplier’s stock valued at $2,142,000 after purchasing an additional 2,047 shares during the last quarter. Institutional investors and hedge funds own 91.02% of the company’s stock.
TRADEMARK VIOLATION WARNING: “West Pharmaceutical Services, Inc. (WST) Expected to Announce Quarterly Sales of $415.53 Million” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/west-pharmaceutical-services-inc-wst-expected-to-announce-quarterly-sales-of-415-53-million/1702555.html.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.